Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App





Russia’s Potential COVID-19 Vaccine Proven Safe and Well-Tolerated in First Clinical Trial

By HospiMedica International staff writers
Posted on 17 Jul 2020
Russia has claimed to have developed a safe vaccine against the novel coronavirus, following the completion of clinical trials of a potential COVID-19 vaccine candidate that was developed locally.

The Sechenov University (Moscow, Russia) has finished a clinical study of the COVID-19 vaccine developed by the Gamalei Institute of Epidemiology and Microbiology (Moscow, Russia). More...
This is the first and only Russian-made vaccine against COVID-19 shortlisted by the World Health Organization in their report on 23 clinical trials around the world.

For the trials, the Sechenov University recruited 38 healthy volunteers, out of which the first group of 18 people received the vaccine on June 18 and the second group of 20 people on June 23. The tested vaccine has been proved safe for the patients, which was the key result of the clinical study, according to Yelena Smolyarchuk, Head of the Sechenov University Centre for Expert Evaluation of Medicinal Products.

Additionally, the Russian Defense Ministry has reported that the vital signs of the volunteers remained within normal limits for 28 days after vaccination. All the volunteers have been discharged from hospital but will remain under observation for the next six months to see if they develop any health issues due to the vaccine over the long-term. Before being discharged from the hospital, the volunteers were made to undergo a medical check-up and pass a blood test to find out if they had developed an immune response to the SARS-CoV-2 virus.

In a video released by the Defense Ministry, researcher Svetlana Volchikhina said, “Their immunity is working well, antibodies are being created, they are protected against the coronavirus.” The results of the trials ‘allow us to speak with confidence about the safety and good tolerability of the vaccine,’ the Defense Ministry said in a statement.

Related Links:
Sechenov University
Gamalei Institute of Epidemiology and Microbiology



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
External Defibrillator
HeartSave Y | YA
Silver Member
ECG Management System
NEMS Web
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.